BACKGROUND/OBJECTIVES: Growing evidence suggests that antibiotic use is associated with childhood body mass index (BMI), potentially via mechanisms mediated by gut microbiome alterations. Less is known on the potential role of prenatal antimicrobial use in offspring obesity risk. We examined whether prenatal antibiotic or antifungal use was associated with BMI at the age of 2 years in 527 birth cohort participants. METHODS/SUBJECTS: Antimicrobial use was obtained from the prenatal medical record. Height and weight were measured at the age of 2 years. Overweight/obesity was defined as a BMI ⩾ 85 th percentile. RESULTS: A total of 303 (57.5%) women used antibiotics and 101 (19.2%) used antifungals during pregnancy. Prenatal antifungal use was not associated with child BMI at the age of 2 years. In the fully adjusted model, prenatal antibiotic use was associated with a 0.20 ± 0.10 (P = 0.046) higher mean BMI Z-score at the age of 2 years. Associations between prenatal antibiotic use and childhood BMI varied by trimester of exposure, with first or second-trimester exposure more strongly associated with larger BMI at the age of 2 years for both BMI Z-score (interaction P = 0.032) and overweight/obesity (interaction P = 0.098) after covariate adjustment. CONCLUSIONS: Prenatal antibiotic, but not antifungal, use is associated with larger BMI at the age of 2 years; associations were stronger for antibiotic exposures in earlier trimesters. Future studies examining whether these associations are due to alterations in the maternal and/or infant microbiome are necessary. Children who are overweight at the age of 2 years are at higher risk for being overweight as they age; prenatal antibiotic use is a potentially modifiable exposure that could reduce childhood obesity.
INTRODUCTION
Rates of childhood overweight and obesity continue to rise in the United States. 1 Rates of medication use in pregnancy have also increased, with antibiotics being among the most commonly administered prescription drugs. 2 In the Project Women and Infants Starting Healthy Study conducted in San Francisco between 2001 and 2002, over half of all women were prescribed a prescription drug during pregnancy, with 62% of those prescriptions being antibiotics. 3 Because of the established impact of antimicrobials on the gut microbiome, 4 and murine studies demonstrating that administration of subtherapeutic concentrations increases adiposity, 5 their administration during pregnancy has the potential to be obesogenic. 6 Antibiotics have been used in animal husbandry for over 6 decades to increase livestock weight gain, with administration to young, but not mature animals, resulting in increased weight. [6] [7] [8] Antibiotic exposure in infancy is associated with increased childhood body mass index (BMI) and/or risk of overweight/obesity. 9, 10 There is limited and conflicting evidence exploring prenatal antibiotic use with childhood obesity. Two studies have shown positive associations between prenatal antibiotic use and overweight/obesity at the age of 7 years 11 or at ages 7-16 years; 12 in contrast, in another study, prenatal antibiotic orders were not associated with child BMI Z-score at the age of 3 years. 13 Fungal species also influence gut symbiosis. 14 However, in contrast to antibiotics, antifungals have not been shown to have an impact on weight in animals. 8 Antifungal medications are commonly used by pregnant women, most often for vaginal candidiasis. 15 In non-pregnant, reproductive age women, topical antifungal treatment of Candida infection alters the bacterial vaginal microbiome, 16 suggesting that use of these agents during pregnancy could potentially alter offspring's risk of obesity via vertical transmission of an altered vaginal microbiome during the birthing process.
To our knowledge, however, no study has examined the association of prenatal antimicrobial use (antibiotic or antifungal use, separately) with BMI in early childhood, overall and within each trimester. We examined the association of prenatal antimicrobial use with childhood BMI at the age of 2 years in the Wayne County Health, Environment, Allergy and Asthma Longitudinal Study (WHEALS) birth cohort. 17, 18 
MATERIALS AND METHODS
WHEALS recruited pregnant women who delivered from September 2003 through December 2007, and who were seeing a Henry Ford Health System obstetrics practitioner at one of five clinics. 17, 18 All women were in their second trimester or later, aged 21-49 years, and lived in a predefined geographic area that was selected to encourage racial and socioeconomic diversity (city of Detroit and surrounding suburban areas). All participants provided written informed consent. Study protocols were approved by the Institutional Review Board at Henry Ford Health System.
Definition of antimicrobial use
As part of a study specifically examining racial (that is, black-white) differences in vitamin D, maternal prenatal and delivery medical records were abstracted for data including antimicrobial use. Antibiotic use was defined as systemic antibiotic use (ingestion, intravenous and intramuscular) at any time during pregnancy. Antifungal use was defined as use of a systemic (ingested) or vaginally applied antifungal medication any time during pregnancy. 18 We defined use of antimicrobials by trimester as follows: first trimester if used between 0 and o14 weeks' gestational age; second trimester if used at 14-o27 weeks' gestational age; and third trimester if used at 27 weeks' gestational age through, and including, delivery. Number of prenatal antibiotics used was categorized as 0, 1, 2-3 or 4+. 19 Antibiotics were classified based on structure/mode of action into the following groups: aminoglycosides, cephalosporins, lincosamides, quinolones, macrolides, nitroimidazoles, nitrofurantoins, penicillins, vancomycins and sulfonamide/trimethoprims. [20] [21] [22] Covariate measurement Maternal date of birth, race, marital status, household income, education, number of previous births and breastfeeding at 1 month were selfreported. Medical records were abstracted to obtain height and weight at first prenatal care visit, prenatal antiviral use, mode of delivery, gestational age at delivery and infant birthweight. Gender-and gestational ageadjusted birthweight Z-scores were calculated using the US population as reference. 23 Child medical records were abstracted to obtain information on antibiotic use before 1 and 6 months of age.
Child body size measurement
At the study's 2-year research clinic visit, trained field staff measured child height in stocking feet with a wall stadiometer; child weight was measured with the child in light clothing using a balance beam physician scale. BMI Z-scores and percentiles were calculated according to the 2000 Centers for Disease Control and Prevention age-and gender-specific growth charts. Overweight was defined as BMI between the 85 th and 95 th percentiles and obesity as BMI ⩾ 95th percentile.
Statistical analysis
Maternal, newborn and child characteristics were compared by prenatal antibiotic or antifungal exposure using a χ 2 -test of independence for discrete characteristics and a Student's t-test for continuous characteristics.
Logistic regression was used to examine the association between prenatal antibiotic or antifungal use and overweight/obesity (BMI ⩾ 85 th percentile); linear regression was used for BMI Z-score. Models were fit unadjusted and adjusted for infant gender, mode of delivery (cesarean section or vaginal), ever breastfed, maternal age, maternal education, maternal race (white or black), birthweight Z-score, child age (in months) at the 2-year visit and maternal BMI at first prenatal care visit. To examine whether associations varied by mode of delivery, child gender, maternal race or ever breastfed, multiplicative interaction terms were fit. Similar models were fit to determine whether type of antibiotic (ever use of cephalosporin, ever use of macrolide, ever use of nitroimidazole, ever use of nitrofurantoin, ever use of penicillin or ever use of other antibiotic (aminoglycoside, lincosamide, quinolone, vancomycin or sulfonamide/ trimethoprim) was associated with BMI at the age of 2 years.
To test for differences in timing of antibiotic or antifungal exposure across pregnancy, multiple informant models were used, which allowed us to test differences in an exposure-outcome relationship across time windows while maintaining the effect estimates that would be obtained fitting separate regression models for each time point. 24 A score test of the equality of all the trimester-specific parameter estimates was used to evaluate differences across trimesters. 24 A generalized estimating equation approach with linear and logistic regression was utilized to fit the multiple informant models for BMI Z-score and overweight/obesity, respectively.
Not all WHEALS children completed a 2-year clinic visit. 17 To account for loss to follow-up, we calculated inverse probability weights for complete follow-up. 25 Inverse probability weights were calculated by fitting a logistic regression model for complete follow-up at the age of 2 years with the following baseline maternal factors: age, race, insurance type, income (including whether or not the question was answered), education, smoking status, prenatal alcohol use, urban residence, marital status, history of asthma/allergies and mode of delivery and obtaining the predicted probability of successful follow-up. Data were reanalyzed using the inverse probability weight as model weights to adjust for bias due to incomplete follow-up. SAS version 9.4 (SAS Institute, Cary, NC, USA) was used for all analyses.
RESULTS
A total of 1258 children were originally included in WHEALS; 659 of these children completed a 2-year clinic visit with height and weight measurement. We excluded 108 children for whom the maternal chart was not abstracted and 24 children for whom maternal antimicrobial use was unknown. We compared maternal and child characteristics between the 527 children included in the sample and the 731 excluded from the analytic sample; compared with those excluded, those included tended to have slightly older maternal age at delivery (30.1 versus 29.2 years), to be black (69.3% versus 56.5%) and to be slightly larger at birth (3349 versus 3270 g; all P o 0.05).
In our study, 303 (57.5%) women had antibiotic use and 101 (19.2%) had antifungal use during pregnancy. There were 577 antibiotic courses and 131 antifungal courses in the 527 women, giving a total of 1.09 antibiotic and a total of 0.25 antifungal courses per pregnancy in our cohort. Nearly all the antibiotic courses (538/577 (93.2%)) were systemic (commonly oral administration); 24 (4.2%) antibiotic courses were delivered vaginally; and only 15 (2.6%) were delivered topically. Compared with women not exposed to antibiotics, those with antibiotic exposure were slightly younger, were more likely to be black, had lower household income, lower education levels, had greater prenatal antiviral exposure and were less likely to ever breastfeed (Table 1) . Black women, those with lower household income, those exposed to an antiviral prenatally and women carrying a male child were more likely to have prenatal antifungal use (Table 1) . There was no association of prenatal antibiotic or antifungal use with child use of antibiotic before 1 or 6 months of age (all P40.14).
Prenatal antimicrobial use and BMI at the age of 2 years The mean BMI of the WHEALS children at the age of 2 years was 16.6 ± 1.7 kg m −2 and the mean BMI Z-score was 0.08 ± 1.1; 90 (17.1%) WHEALS children were overweight/obese at the age of 2 years. There was no evidence that prenatal antibiotic use was associated with overweight/obesity risk and there was no evidence that prenatal antifungal medication use was associated with BMI Z-score or overweight/obesity at the age of 2 years (Table 2 ). Prenatal antibiotic use was positively associated with BMI Z-score at the age of 2 years (P = 0.046); after covariate adjustment, children born to mothers who used antibiotics in the prenatal period had an estimated 0.20 ± 0.10 unit higher BMI Zscore at the age of 2 years compared with children born to mothers who did not use prenatal antibiotics (Table 2 ). There was no evidence that the association between prenatal antibiotic or antifungal medication use with child BMI varied by mode of delivery, child gender, maternal race or breastfeeding status (all interactions P40.11).
Although there was no evidence of a prenatal antibiotic-bydelivery mode interaction with childhood BMI, given our a priori hypothesis that the maternal microbiome may mediate associations between prenatal antibiotic use and childhood obesity, we refit our models stratified by the delivery mode. In the fully adjusted model, prenatal antibiotic use was not statistically significantly associated with BMI Z-score at the age of 2 years (0.17 ± 0.18; P = 0.35) in offspring of women who delivered via C-section; in contrast, the association of prenatal antibiotic use with BMI Z-score at the age of 2 years (0.23 ± 0.13; P = 0.064) approached statistical significance in women who delivered vaginally. Trimester-specific antimicrobial use and BMI at the age of 2 years Trimester of prenatal antibiotic exposure was associated with BMI Z-score and overweight/obesity at the age of 2 years (Table 3 ). In the fully adjusted model, there was evidence for a trimester-specific effect of antibiotic use with BMI Z-score (interaction P = 0.032); first-trimester antibiotic use was associated with a 0.21 ± 0.12 unit higher BMI Z-score (P = 0.071), second-trimester antibiotic use was associated with a statistically significant 0.28 ± 0.13 unit higher BMI score (P = 0.028), but third-trimester use was not associated with BMI Z-score (P = 0.691). Results were similar for odds of overweight/obesity; in the fully adjusted model, there was borderline suggestive significant evidence of a trimester-specific effect of antibiotic use (interaction P = 0.098). Children born to mothers who used antibiotics in the first trimester had 1.78 (95% CI OR: 1.07, 2.98) times greater odds of being overweight/obese at the age of 2 years (P = 0.028); there was no association of second or third-trimester antibiotic use and odds of overweight/obesity at the age of 2 years. There was no evidence for a trimesterspecific effect of antifungal use on childhood BMI at the age of 2 years. Dose-response relationship with antibiotic use Most women who used antibiotics had one exposure over pregnancy (n = 157; 51.8%; Table 1 ). Figure 1 shows the relationship between number of prenatal antibiotics used and the mean BMI Z-score at the age of 2 years, with the highest BMI Z-score seen in children with the greatest number of prenatal exposures to antibiotics; however, this was not statistically significant (P-trend = 0.144). There was no association of number of antibiotics used with overweight/obesity.
Only 17 women had multiple uses of antifungal medications (Table 1) , thus we did not evaluate potential dose-response relationships for antifungal use.
Antibiotic type and BMI Antibiotic use fell into the following groupings: ever penicillin use (n = 189 uses); ever nitroimidazole use (n = 112 uses); ever cephalosporin use (n = 87 uses); ever nitrofurantoin use (n = 72 uses); ever macrolide use (n = 62 uses); and ever use of other antibiotics (n = 55 uses). After covariate adjustment, compared with children born to women without antibiotic exposure, children born to a mother ever exposed to macrolides had a statistically significantly higher BMI Z-score (0.37 ± 0.18; P = 0.039). No other antibiotic type was associated with BMI Z-score. Antibiotic type was also not associated with overweight/obesity.
Sensitivity analysis
Model inferences were similar after accounting for inverse probability weight. In the fully adjusted model, the association of use of prenatal antibiotics with BMI Z-score was slightly attenuated (β = 0.19 ± 0.11; P = 0.069). There remained evidence for a trimester-specific effect of prenatal antibiotic use on BMI Zscore (interaction P = 0.035) and overweight/obesity (interaction P = 0.069). First-trimester antibiotic use was associated with a mean increase in BMI Z-score of 0.21 ± 0.12 (P = 0.069) and secondtrimester antibiotic use was associated with a mean increase in BMI Z-score of 0.29 ± 0.13 (P = 0.023). First-trimester antibiotic use was also associated with a 1.85 (95% CI: 1.09, 3.16; P = 0.023) times increased odds of overweight/obesity.
DISCUSSION
In the current study, prenatal antibiotic, but not antifungal, exposure was associated with an increased risk of offspring having a larger BMI Z-score at the age of 2 years. We provide new evidence suggesting that this association varies by timing of the antibiotic exposure, with antibiotic exposure in the first or second trimester, but not the third trimester, associated with greater BMI Z-score at the age of 2 years. Similarly, exposures to antibiotics in the first trimester were associated with overweight/obesity at at the age of 2 years. Even at early ages, children who are obese are at higher risk of becoming obese adolescents and adults; 26 prenatal antibiotic use may be one modifiable exposure that could reduce the current rates of childhood obesity, particularly if we are able to reduce unnecessary antibiotic use. Antibiotic use during pregnancy is associated with alterations in the vaginal microbiome at gestational week 36, with significantly increased Staphylococcus species in women treated with oral antibiotics. 27 Particularly in vaginally born infants, the infant gut, skin and oral microbiome resembles the maternal vaginal microbiome. 28 Children with greater Staphylococcus aureus counts in fecal samples from 6 or 12 months of age are statistically significantly more likely to be overweight at at the age of 7 years. 29 Thus, if prenatal antibiotic exposure increases vaginal Staphylococcus aureus numbers, this could explain the increased risk of larger BMI at at the age of 2 years detected in our study. In animal models, maternal antibiotic treatment is associated with alterations in the offspring gut microbiome. 30 Although intrapartum maternal antibiotic use in Group B Streptococcus-positive mothers is associated with alterations in the infant gut microbiome, 31, 32 to our knowledge, data from humans examining whether prenatal antibiotic use over various gestational ages is associated with infant gut microbiome are lacking. Antibiotic use during the last month of pregnancy was not associated with the infant gut microbiome at at the age of 1 month, 33 which is consistent with our finding that third-trimester antibiotic exposure is not associated with childhood BMI at at the age of 2 years. Given the microbial dynamics that occur normally in the maternal gut and vaginal microbiome over pregnancy, [34] [35] [36] which are postulated to have a role in priming fetal development, it is plausible that antibiotic-associated maternal microbiome perturbation may have an impact on postnatal infant microbiome development, and, subsequently, child health measures. Our results, which showed a stronger, albeit only near statistically significant association of maternal antibiotic use with BMI Z-score at the age of 2 years in children delivered vaginally compared with those delivered by C-section further suggest that alterations in the microbiome may be a mechanism linking maternal antibiotic use with childhood BMI.
In addition to mechanisms linked to the microbiome, differential timing of antibiotics over gestational development could directly have an impact on the developing endocrine system, and thus prime a fetus for future risk of obesity. Development of the human endocrine system commences at approximately gestational week 4, involving hormone production related to subsequent fetal growth in gestational weeks 4-10. 37 In contrast, fetal adipose tissue deposition primarily occurs throughout the latter third of gestation. 38 Hence, exposures at distinct periods of gestation may have a differential impact on fetal development. For instance, data from several studies conducted on pregnancies that occurred during famines suggest that timing of the exposure, that is, undernutrition in early pregnancy, may be important for increased risk of offspring obesity. 39 Maternal antibiotic use may have a similar trimester-specific effect on the fetal endocrine system and development.
Alternative mechanisms by which prenatal antibiotic exposure may have an impact on childhood BMI are possible. Antibiotic exposure could have an impact on the development, implantation or function of the placenta, subsequently affecting development of the fetus and future growth. Limited data exist describing the impact of antibiotics on the placenta; however, in a recent study examining amniotic membrane samples from a single placenta, antibiotic exposure damaged the cell membrane and resulted in loss of microvillia. 40 The placenta undergoes rapid development during the first trimester of pregnancy 41 and itself has a distinct microbiome that resembles the oral microbiome; 42 antibiotic exposure early in pregnancy may have a similar impact on the placental microbiome at a critical stage of fetal development. Data from the Project Viva cohort demonstrated a trimester-specific effect of antibiotic exposure on leptin, a hormone involved in energy balance and appetite suppression; exposures in the first and second trimesters were associated with non-statistically significant lower levels of cord blood leptin, whereas exposures in the third trimester were associated with statistically significant higher levels of cord blood leptin. 43 Lower cord blood leptin levels are associated with higher BMI at the age of 3 years. 44 Thus, although the associations were not statistically significant, the finding of lower leptin in cord blood following first or secondtrimester antibiotic exposure is consistent with our finding that earlier pregnancy antibiotic exposure is associated with larger BMI at the age of 2 years. Finally, prenatal exposure to antibiotics could increase the risk of antibiotic use in early childhood, which is known to increase the risk of obesity; 45 however, in our cohort, prenatal antibiotic use was not associated with early-childhood antibiotic use, suggesting that this was not acting as a confounder in our study. However, each of these potential mechanisms requires further study.
To our knowledge, few previous studies specifically examined prenatal antibiotic use and childhood BMI, and none have examined antifungal use. In the Northern Manhattan Mothers and Children study, antibiotic exposure in the second or third trimester was associated with risk of obesity and BMI Z-score at the age of 7.
11 In contrast to our findings at the age of 2 years, first-trimester antibiotic use was not associated with childhood BMI at the age of 7 years. Similarly, in a study of Danish schoolchildren aged 7-16 years, prenatal antibiotic exposure was associated with overweight and obesity risk. 12 In a study conducted in Geisinger Clinic data, however, prenatal antibiotic orders were not associated with BMI Z-score at the age of 3 years. 13 There are several differences in these studies, which may explain some of these varying results. Antibiotic use in WHEALS was defined based on medical chart review, compared with selfreport during a third-trimester interview in the Northern Manhattan study; women may have difficulty self-reporting medication use, particularly early in pregnancy. The prevalence of antibiotic use in WHEALS in the second and third trimesters was 32.1% compared with 16% in the Northern Manhattan study and 33% in the Danish study, and 60.4% of women in the Geisinger study were ordered antibiotics prenatally. Whereas WHEALS comprises primarily black and white women, the Northern Manhattan study primarily comprises black and Dominican women, the Danish study consisted of Dutch women and the Geisinger study was nearly all white. Finally, the age at childhood BMI measurement (age 2 in WHEALS versus age 7 years in the Northern Manhattan Study, age 7-16 years in the Danish study and age 3 years in the Geisinger study) differed. Electronic health record data were used to define child BMI at the age of 3 years in the Geisinger study, compared with measurements obtained by research staff in WHEALS. Overall, there is evidence to support a role for prenatal antibiotic use and childhood BMI; future studies that address BMI trajectories throughout childhood are needed.
We found evidence to suggest that macrolide antibiotic use in pregnancy was associated with higher BMI Z-score at the age of 2 years. One recent study of antibiotic exposure in the first year of life showed that each class of antibiotic studied (narrow spectrum, broad spectrum and macrolides) was associated with weight gain though the age of 8 years. 45 Saari et al. 9 found that macrolide use in infancy had the greatest impact on weight gain in children through the age of 24 months; these authors attributed this to pharmacokinetic properties of macrolides, which are excreted in bile and thus may have direct contact with microbiota in the colon, compared with the other classes of antibiotics, which are eliminated by the kidneys. In a study of 142 Finnish children aged 2-7 years, macrolide, but not penicillin use was associated with a persistent change in the composition and function of the gut microbiome; macrolide use was also positively associated with BMI Z-score. 22 Findings were similar in a mouse model; tylosin, a veterinary medicine macrolide, given shortly after weaning, increased both total and lean mass of mice, compared with only lean mass increases in mice exposed to amoxicillin. 46 Further, tylosin was also associated with microbiota composition changes that persisted longer than changes in amoxicillin-exposed mice. 46 Together, these studies support a potential microbiome-mediated role linking certain antibiotics with increases in BMI. Given that a number of women in our study used multiple antibiotic classes over pregnancy, however, these findings will require replication in a larger study that will permit exploration of the different combinations of antibiotics typically used over pregnancy.
We found no evidence that prenatal antifungal use was associated with offspring obesity risk. Although treatment of Candida infection alters the bacterial vaginal microbiome, 16 there are limited existing data on the type of changes that occur in the vaginal microbiome as a result of antifungal use and how those changes are transmitted to offspring. Given the propensity for microbiota re-assembly following perturbation, topical antifungal treatment of vaginal infection, which was the most common route of exposure in our study, may only be pertinent in the period immediately before birth.
There are several limitations to the current investigation. We assigned antimicrobial use to a specific trimester based on pregnancy dating information; inaccurate reporting of last menstrual period, for instance, may have resulted in incorrect assignment of exposure time. Although information on antimicrobial use was obtained from the medical record and thus is not subject to recall bias, we do not have information on whether or not the woman took the medication as prescribed. We do not have comprehensive information on the symptoms or specific illnesses that led to the use of prenatal antibiotics; thus, we cannot rule out that the associations detected are a result of an underlying infection. The infectious agents themselves, rather than the subsequent antimicrobial use, could have an impact on child growth. 47 A recent longitudinal birth cohort study from Kaiser Permanente Northern California suggested that childhood infection, rather than overall early-childhood antibiotic use, was associated with childhood obesity; however, consistent with our overall hypothesis, in this study, early infancy antibiotic use (first 6 months of life) was associated with childhood obesity. 48 To our knowledge, however, similar studies have not been conducted during pregnancy, and thus future work to examine prenatal infection with and without antibiotic use may be needed.
CONCLUSIONS
We found evidence suggesting that prenatal antibiotic use, but not antifungal use, is associated with childhood BMI at the age of 2 years. Higher BMI Z-score and risk of overweight/obesity were greatest for children with maternal exposures during the first or second trimester. Inappropriate antibiotic use during pregnancy is common. 49 Although there are clear indications for antibiotic use during pregnancy, inappropriate maternal antibiotic use (such as for upper respiratory infection of probable viral origin 50 ) may contribute to the childhood obesity epidemic. Additional studies examining whether changes in the gut microbiome (both maternal and offspring) mediate associations between prenatal antibiotic use and childhood BMI are warranted.
